XNW4107 clinical trials
Also written XNW4107.
How each study uses XNW4107 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the XNW4107 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses XNW4107 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)Not yet recruitingPhase 3Evopoint Biosciences Inc.NCT05204368Written as Combination of Imipenem/Cilastatin and XNW4107
- Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)CompletedPhase 3Evopoint Biosciences Inc.NCT05204563Written as Combination of Imipenem/Cilastatin and XNW4107
- Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal FunctionCompletedPhase 1Evopoint Biosciences Inc.NCT04787562Written as XNW4107, Imipenem/Cilastatin
- Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/CilastatinCompletedPhase 1Evopoint Biosciences Inc.NCT04482569Written as XNW4107
- Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy SubjectsCompletedPhase 1Evopoint Biosciences Inc.NCT04802863Written as XNW4107, Imipenem/Cilastatin
- To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.CompletedPhase 1Evopoint Biosciences Inc.NCT04801043Written as XNW4107